公司簡介
ARJIL Pharmaceuticals LLC, founded in 2014, is a development stage specialty pharmaceutical company which focused on advancing and commercializing innovative medical products. Since its inception, Arjil are committed to the ongoing discovery, development and delivery of botanical basis medicines for elderly globally.
The contributed capital of Arjil in 2020 is up to 108.9 M.
吳郁彬 董事長
在美國行醫近40年退休後投入生技醫藥產業
美國紐約大學 Bellevue Hospital
美國紐澤西 建立疼痛及麻醉臨床中心
美國紐澤西 Zeitech Corp 董事長
美國芝加哥 Arch Venture Fund
美國紐澤西 TBS Pharmaceutical Company 董事
美國紐澤西 Barjil Investment Group 總裁
公司團隊
Biomedical Technology and Device
Research Laboratories, ITRI
Natural product isolation
NTOU, Master
Hui-Ju Liang
Product Manager
趙麗玲 博士
財務長
彰化師範大學
東海大學
靜宜大學
崇碁綠能科技股份有限公司
中興大學 生技所 博士
中興大學 生技所 博士後研究員
陳銘坤 博士
經理
Richard Wu, MD
醫學顧問
蔡秀娟 博士
名譽顧問 美國
急救照護及胸腔專科
哥倫比亞大學
前工業技術研究院生醫所副所長
Roche Former Director
研究服務
We are committed to developing medicines for unmet medical needs and improving quality life products, including bioactive botanical cosmetic ingredients, healthy foods derived from botanical drugs, and anti-aging products for improving and extending quality of life for elderly people.
研究量能
With the QMS (Quality Management System) having been established on our organization infrastructure along the IND process, we have been holistically approaching and accelerating our drug R&D in data driven & risk managed (assessed) manners, and consistently moving toward a successful track in a predictable way.